TransMedics Group (NASDAQ:TMDX) Trading 6.5% Higher – Should You Buy?

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) rose 6.5% during mid-day trading on Tuesday . The company traded as high as $73.00 and last traded at $73.21. Approximately 277,077 shares changed hands during trading, a decline of 89% from the average daily volume of 2,631,531 shares. The stock had previously closed at $68.76.

Analyst Ratings Changes

A number of analysts recently commented on the company. TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Robert W. Baird reduced their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday. Finally, Piper Sandler dropped their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The business’s 50-day moving average is $66.67 and its two-hundred day moving average is $110.42. The company has a market capitalization of $2.47 billion, a P/E ratio of 78.16 and a beta of 2.12.

Insiders Place Their Bets

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in shares of TransMedics Group by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock worth $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock worth $94,061,000 after buying an additional 30,092 shares during the last quarter. Vaughan Nelson Investment Management L.P. increased its position in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after buying an additional 32,605 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of TransMedics Group by 9.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company’s stock valued at $18,545,000 after buying an additional 25,739 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after buying an additional 34,947 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.